Virtual Library

Start Your Search

Qiao Yang



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-16 - Predictive Markers for Efficacy in Malignancies Treated with Immune Checkpoint Inhibitors (Now Available) (ID 2171)

      08:00 - 18:00  |  Author(s): Qiao Yang

      • Abstract
      • Slides

      Background

      Predictive markers for tumor response and efficacy of immune checkpoint inhibitors (ICIs) are still controversial. Measurements of the widespread biomarkers, such as PD-L1 expression or tumor mutational burden, are invasive and costly. Therefore, we investigated several accessible factors to predict prognosis.

      Method

      Clinicopathologic features and previous treatment records were collected from 64 patients with diverse malignancies between 2016 and 2018 in oncology department of Xinqiao hospital. Endpoints were progression free survival (PFS) and best overall response (bOR). The best cut-off points of continuous variables were determined by R. Kaplan-Meier was applied to analyze survival. The correlations between bOR and biomarkers were analyzed by Chi-square test.

      Result

      After a median follow-up of 5.5 months, a significant improvement in PFS was observed in 38 patients with higher body mass index (BMI, cut-off=21.45kg/m2) compared to the other 26 patients (10.0 months vs 4.6 months, p=0.015), also the former experienced a tendency of higher bOR rate (28.9% vs 11.5%, p=0.178). Moreover, patients who had radiotherapy records experienced better PFS (12.3 months vs 4.5 months, p=0.019) and higher bOR rate (26.1% vs 19.5%, p=0.542) than the others. Further, receiving antibiotics during immunotherapy was a negative factor in the prognosis of ICIs, which led to worse PFS (4.2 months vs 9.7 months, p=0.019) and lower bOR rate (8.3% vs 25.0%, p=0.383) than its counterparts.wclc.jpg

      Conclusion

      Higher BMI and radiotherapy records are associated with better clinical outcomes of immunotherapy, while receiving antibiotics is negatively correlated with efficacy of ICIs.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.04 - Immuno-oncology (ID 164)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.04-29 - Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies (Now Available) (ID 1677)

      09:45 - 18:00  |  Author(s): Qiao Yang

      • Abstract
      • Slides

      Background

      PD-L1 expression in malignant tumor tissues is a rational biomarker to predict the efficacy and prognosis of anti-PD-1/anti-PD-L1 treatment, but few studies focus on the role of blood PD-L1 expression.

      Method

      Fifty-one paired tissue samples and blood samples, as well as clinicopathologic features, were collected from patients with diverse malignancies to investigate the correlation among tissue PD-L1 (tPD-L1) expression, plasma PD-L1 mRNA expression, soluble PD-L1 (sPD-L1) expression and clinicopathologic features. Tissue PD-L1 were measured by immunohistochemistry. PD-L1 mRNA and self-designed plasma external reference PLACON were measured by quantitative real-time PCR. Soluble PD-L1 were detected by ELISA kit. Then, dynamic changes of blood PD-L1 expression (at baseline and within 2 months) were measured to evaluate the efficacy of patients with malignancies (n=24) who received anti-PD-1/anti-PD-L1 treatment.

      Result

      Moderate correlation between tPD-L1 and PD-L1 mRNA (r=0.62, P<0.001), weak correlation between tPD-L1 and sPD-L1 (r=0.37, P=0.007) and weak correlation between PD-L1 mRNA and sPD-L1 (r=0.32, P=0.02) were found. Most clinicopathologic features had no significant correlation with PD-L1 mRNA and sPD-L1 expression. Interestingly, patients without metastasis had higher PD-L1 mRNA and sPD-L1 expression than counterparts. Further, patients with over 2.03-fold PD-L1 mRNA increase (n=11) during treatment experienced improved progression-free survival (PFS) than those with less than 2.03-fold increase (n=13), these patients also had higher best overall response (bOR) rate (45.45% vs. 7.69%). By comparison, the dynamic changes of sPD-L1 expression had no significant correlation with PFS and bOR.

      figure 1677.jpg

      Conclusion

      Our study demonstrates that plasma PD-L1 mRNA expression was significantly correlated with tissue PD-L1 expression, and provides proof for the application of plasma PD-L1 mRNA as a predictor for anti-PD-1/anti-PD-L1 treatment.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.